JP2024534156A5 - - Google Patents
Info
- Publication number
- JP2024534156A5 JP2024534156A5 JP2024513002A JP2024513002A JP2024534156A5 JP 2024534156 A5 JP2024534156 A5 JP 2024534156A5 JP 2024513002 A JP2024513002 A JP 2024513002A JP 2024513002 A JP2024513002 A JP 2024513002A JP 2024534156 A5 JP2024534156 A5 JP 2024534156A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- structural
- combination
- amodiaquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20210100572 | 2021-08-27 | ||
| GR20210100572 | 2021-08-27 | ||
| PCT/IB2022/058008 WO2023026247A1 (en) | 2021-08-27 | 2022-08-26 | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534156A JP2024534156A (ja) | 2024-09-18 |
| JP2024534156A5 true JP2024534156A5 (https=) | 2025-09-02 |
Family
ID=83598699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513002A Pending JP2024534156A (ja) | 2021-08-27 | 2022-08-26 | Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240366729A1 (https=) |
| EP (1) | EP4392033A1 (https=) |
| JP (1) | JP2024534156A (https=) |
| CN (1) | CN118284417A (https=) |
| WO (1) | WO2023026247A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220265776A1 (en) * | 2019-07-09 | 2022-08-25 | Genesis Pharma Sa | Combination |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140256626A1 (en) | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
| ES2791301T3 (es) * | 2015-11-06 | 2020-11-03 | Genesis Pharma Sa | Combinación de canrenoato y exenatida |
| EP3498279A4 (en) * | 2016-08-12 | 2020-04-29 | Novmetapharma Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES |
| US20220265776A1 (en) | 2019-07-09 | 2022-08-25 | Genesis Pharma Sa | Combination |
-
2022
- 2022-08-26 US US18/684,454 patent/US20240366729A1/en active Pending
- 2022-08-26 EP EP22786094.7A patent/EP4392033A1/en active Pending
- 2022-08-26 JP JP2024513002A patent/JP2024534156A/ja active Pending
- 2022-08-26 WO PCT/IB2022/058008 patent/WO2023026247A1/en not_active Ceased
- 2022-08-26 CN CN202280071517.2A patent/CN118284417A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101843897B (zh) | 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂 | |
| US20190263810A1 (en) | Fluorinated integrin antagonists | |
| JP2023543059A5 (https=) | ||
| US20110218515A1 (en) | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | |
| US8106058B2 (en) | Anti-arenaviral compounds | |
| US20220160872A1 (en) | Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery | |
| JP2024534156A5 (https=) | ||
| JP2023071933A5 (https=) | ||
| PL187085B1 (pl) | Preparat farmaceutyczny do leczenia i/lub zapobiegania zakażeniom HIV | |
| EA032263B1 (ru) | Применение ингибиторов ccr3 | |
| Roarty et al. | Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome | |
| US20100113347A1 (en) | Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes | |
| CZ57896A3 (en) | The use of quinoxalines in combination with protease inhibitors as medicaments for treating aids and/or hiv infections | |
| JP2024520132A (ja) | 向知性薬としてのｌｉｎｅ－１阻害剤 | |
| JP2022540198A5 (https=) | ||
| ES2200052T3 (es) | Politerapia contra la infeccion por vih usando el inhibidor de la proteasa del vih indinavir y el inhibidor de la transcriptasa inversa 3tc, opcionalmente junto con azt. | |
| US9242009B2 (en) | Compositions and methods to treat neurodegenerative diseases | |
| US12090163B2 (en) | Pharmaceutical compositions | |
| US20230174510A1 (en) | N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof | |
| EP1165074A2 (en) | Viral treatment | |
| JPS62187411A (ja) | １−（３′，４′−ジエトキシベンジル）−６，７−ジエトキシ−３，４−ジヒドロイソキノリニウム−テオフイリン−７−アセテ−トからなる医薬組成物 | |
| JPH0848631A (ja) | 血管透過性亢進抑制剤 | |
| US20160303146A1 (en) | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders | |
| US20240041854A1 (en) | Cold medicine and antiviral medicine | |
| Huichapa | Medical Management of Herpes Simplex Keratitis |